Vapotherm Cuts FY23 Revenue Guidance From $70M-$73M To $69M--$71M
$VAPO
Medical/Dental Instruments
Health Care
Vapotherm Cuts FY23 Revenue Guidance From $70M-$73M To $69M--$71M
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/6/2022 | $12.00 → $5.00 | Buy → Hold | Canaccord Genuity |
| 4/7/2022 | $23.00 → $8.00 | Overweight → Underweight | Piper Sandler |
EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem
EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.
EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b
Canaccord Genuity downgraded Vapotherm from Buy to Hold and set a new price target of $5.00 from $12.00 previously
Piper Sandler downgraded Vapotherm from Overweight to Underweight and set a new price target of $8.00 from $23.00 previously
Piper Sandler reiterated coverage of Vapotherm with a rating of Overweight and set a new price target of $36.00 from $39.00 previously
Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) stock rose 57.8% to $0.38 during Friday's regular session. The market value of their outstanding shares is at $4.4 million. Verrica Pharmaceuticals (NASDAQ:VRCA) stock moved upwards by 51.06% to $5.68. The company's market cap stands at $238.9 million. ASLAN Pharma (NASDAQ:ASLN) shares rose 26.98% to $0.63. The company's market cap stands at $10.5 million. Biophytis (NASDAQ:BPTS) stock increased by 25.16% to $0.81. The company's market cap stands at $7.8 million. Context Therapeutics (NASDAQ:CNTX) shares rose 24.94% to $1.05. The company's market cap stands at $16.7 million. Immix Biopharma (NASDAQ:IMMX) shares increased by 24.51% to $7.07.
This suspension was made because the Company fell below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15 million.
Gainers C4 Therapeutics (NASDAQ:CCCC) stock increased by 100.5% to $2.37 during Tuesday's regular session. The market value of their outstanding shares is at $116.6 million. Aditxt (NASDAQ:ADTX) shares rose 68.94% to $6.42. The market value of their outstanding shares is at $2.8 million. Icosavax (NASDAQ:ICVX) shares rose 48.61% to $15.59. The company's market cap stands at $780.9 million. Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 32.98% to $1.16. The company's market cap stands at $33.4 million. IN8bio (NASDAQ:INAB) shares increased by 29.93% to $1.66. The market value of their outstanding shares is at $53.2 million. PAVmed (NASDAQ:PAVM) stock rose 29.33% to $4.01. The
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b
SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t
4/A - VAPOTHERM INC (0001253176) (Issuer)
15-12G - VAPOTHERM INC (0001253176) (Filer)
EFFECT - VAPOTHERM INC (0001253176) (Filer)
EFFECT - VAPOTHERM INC (0001253176) (Filer)
SC 13D/A - VAPOTHERM INC (0001253176) (Subject)
SC 13D/A - VAPOTHERM INC (0001253176) (Subject)
SC 13G - VAPOTHERM INC (0001253176) (Subject)